Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:60081 |
Name | triple-receptor negative breast cancer |
Definition | A breast cancer that is characterized by the absence of estrogen, progresterone and Her2 receptors. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer triple-receptor negative breast cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Rivoceranib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | AMG 900 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Alisertib + Docetaxel | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Lucitanib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Evofosfamide | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Tirapazamine | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | SN30000 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | PR-104 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | BMS-906024 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Eribulin | triple-receptor negative breast cancer | not applicable | detail... |
NOTCH1 S2449fs | PF-03084014 | triple-receptor negative breast cancer | sensitive | detail... |
NOTCH1 mutant | PF-03084014 | triple-receptor negative breast cancer | sensitive | detail... |
Unknown unknown | KW-2450 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | KW-2450 + Selumetinib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Senexin B | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | BAY1217389 + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | BAY1161909 + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Docetaxel + NTRC 0066-0 | triple-receptor negative breast cancer | not applicable | detail... |
NOTCH1 rearrange | MRK-003 | triple-receptor negative breast cancer | sensitive | detail... |
NOTCH1 rearrange | MRK-003 + SCH772984 | triple-receptor negative breast cancer | no benefit | detail... |
NOTCH1 wild-type | MRK-003 | triple-receptor negative breast cancer | decreased response | detail... |
NOTCH1 rearrange | MRK-003 + Paclitaxel | triple-receptor negative breast cancer | sensitive | detail... |
NOTCH1 wild-type | MRK-003 + Paclitaxel | triple-receptor negative breast cancer | no benefit | detail... |
Unknown unknown | TVB-2640 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | CCT007093 + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | CCT007093 | triple-receptor negative breast cancer | no benefit | detail... |
Unknown unknown | Paclitaxel + Plicamycin | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | LY2109761 + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | SKLB646 | triple-receptor negative breast cancer | not applicable | detail... |
PIK3CA mutant | Palbociclib + Pictilisib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA wild-type | Palbociclib + Pictilisib | triple-receptor negative breast cancer | no benefit | detail... |
SRC positive | KX2-391 | triple-receptor negative breast cancer | sensitive | detail... |
SRC positive | KX2-391 + Paclitaxel | triple-receptor negative breast cancer | sensitive | detail... |
JAK2 over exp | NVP-BSK805 + Paclitaxel | triple-receptor negative breast cancer | sensitive | detail... |
JAK2 amp | NVP-BSK805 + Paclitaxel | triple-receptor negative breast cancer | sensitive | detail... |
JAK2 amp | NVP-BSK805 | triple-receptor negative breast cancer | sensitive | detail... |
Unknown unknown | Alisertib + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
SRC positive | UM-164 | triple-receptor negative breast cancer | predicted - sensitive | detail... |
SRC positive | BIRB-796 + Dasatinib | triple-receptor negative breast cancer | sensitive | detail... |
Unknown unknown | Pemetrexed Disodium + Sorafenib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | YLL545 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Foretinib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Bevacizumab + Capecitabine + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | JQ1 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Birabresib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Docetaxel + JQ1 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | JQ1 + Vinorelbine | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Cisplatin + JQ1 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Carboplatin + JQ1 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | AMG 900 + Ixabepilone | triple-receptor negative breast cancer | not applicable | detail... |
PIK3CA mutant | Pictilisib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA amp | Linsitinib + Pictilisib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA amp | NVP-AEW541 + Pictilisib | triple-receptor negative breast cancer | sensitive | detail... |
Unknown unknown | Selumetinib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Carboplatin + Docetaxel + Gemcitabine + Itraconazole | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | BAY 11-7082 + Erlotinib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Adavosertib + Everolimus | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | YM155 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Bortezomib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Carfilzomib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | KP372-1 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Crizotinib + Navitoclax | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Cabozantinib + Navitoclax | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Navitoclax + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Nutlin-3a + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | JQ1 + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
PIK3CA act mut | Bevacizumab + Doxorubicin + Everolimus | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA act mut | Bevacizumab + Doxorubicin + Temsirolimus | triple-receptor negative breast cancer | predicted - sensitive | detail... |
Unknown unknown | BETd-246 + BM-1197 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | BETd-246 + Navitoclax | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | A-1155463 + BETd-246 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | SY-1365 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Niraparib + SY-1365 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | BPM 31510 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | LY3200882 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | CFI-402257 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Ipatasertib + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
PIK3CA mutant | Ipatasertib + Paclitaxel | triple-receptor negative breast cancer | predicted - sensitive | detail... |
AKT1 mutant | Ipatasertib + Paclitaxel | triple-receptor negative breast cancer | predicted - sensitive | detail... |
Unknown unknown | ONC201 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Docetaxel + ONC201 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | ONC201 + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
AKT1 E17K | Capivasertib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
Unknown unknown | ASTX-660 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | ASTX-660 + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | G-TPP + Navitoclax | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | G-TPP + Obatoclax | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Cisplatin + Everolimus + Paclitaxel | triple-receptor negative breast cancer | no benefit | detail... |
Unknown unknown | Carfilzomib + Tinostamustine | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Bortezomib + Tinostamustine | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Capivasertib + Olaparib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | S63845 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Docetaxel + S63845 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Cyclophosphamide + Doxorubicin + Elenagen | triple-receptor negative breast cancer | not applicable | detail... |
ERBB2 V697L | Neratinib | triple-receptor negative breast cancer | sensitive | detail... |
FGFR2 - TNS1 | Infigratinib | triple-receptor negative breast cancer | sensitive | detail... |
FGFR2 - TNS1 | Buparlisib + Infigratinib | triple-receptor negative breast cancer | sensitive | detail... |
FGFR2 - TNS1 | Buparlisib | triple-receptor negative breast cancer | no benefit | detail... |
Unknown unknown | Triptolide | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Selumetinib + SHP099 | triple-receptor negative breast cancer | not applicable | detail... |
STK11 F354L | Everolimus + Exemestane | triple-receptor negative breast cancer | predicted - sensitive | detail... |
Unknown unknown | AVID200 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | LTX-315 + Pegylated liposomal-doxorubicin | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | CC-671 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Capivasertib + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | MIW815 + Spartalizumab | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | SMI#9-GNP | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Cisplatin + SR-4835 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Irinotecan + SR-4835 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | SR-4835 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | RhFzd7 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Docetaxel + RhFzd7 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Fluzoparib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | GSK3368715 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | BOS172722 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | BOS172722 + Paclitaxel | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Docetaxel + DT2216 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Doxorubicin + DT2216 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | DT2216 + Vincristine Sulfate | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | GSK2801 + JQ1 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | BAZ2-ICR + BI-9564 + JQ1 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | BAZ2-ICR + JQ1 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Birabresib + GSK2801 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | GSK2801 + HY-16462 | triple-receptor negative breast cancer | no benefit | detail... |
Unknown unknown | HY-16462 + JQ1 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | CPI-637 + HY-16462 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Sacituzumab govitecan-hziy | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | MGD013 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Alisertib + Sapanisertib | triple-receptor negative breast cancer | not applicable | detail... |
AKT1 E17K | Capivasertib + Paclitaxel | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA act mut | Capivasertib + Paclitaxel | triple-receptor negative breast cancer | predicted - sensitive | detail... |
Unknown unknown | Olaparib + THZ1 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Enzalutamide + Taselisib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Carboplatin + Gemcitabine + Trilaciclib | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | OMTX705 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Carboplatin + Paclitaxel + RO4929097 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | DLYE5953A | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | RX-5902 | triple-receptor negative breast cancer | not applicable | detail... |
Unknown unknown | Buparlisib | triple-receptor negative breast cancer | no benefit | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00576654 | Phase I | Irinotecan Veliparib | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT00740805 | Phase I | Aldoxorubicin + Cyclophosphamide + Veliparib | Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT01116648 | Phase Ib/II | Olaparib Cediranib + Olaparib | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Recruiting | USA | 2 |
NCT01391143 | Phase I | MGA271 | Safety Study of MGA271 in Refractory Cancer | Completed | USA | 0 |
NCT01562873 | Phase II | Ruxolitinib | Ruxolitinib in Patients With Breast Cancer | Terminated | USA | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | 6 |
NCT01623349 | Phase I | Alpelisib + Olaparib Buparlisib + Olaparib | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | Completed | USA | 0 |
NCT01639248 | Phase II | ENMD-2076 | Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC | Completed | USA | 1 |
NCT01653470 | Phase I | Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | Completed | USA | CAN | 1 |
NCT01695005 | Phase I | LY3039478 | A Study of LY3039478 in Participants With Advanced Cancer | Completed | USA | 5 |
NCT01884285 | Phase I | AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib | AZD8186 First Time In Patient Ascending Dose Study | Completed | USA | CAN | 2 |
NCT01920061 | Phase I | Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) | Completed | USA | CAN | 3 |
NCT01928394 | Phase Ib/II | Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | CAN | 6 |
NCT01931163 | Phase II | Everolimus | NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer | Completed | USA | 0 |
NCT01938638 | Phase I | BAY1143572 | Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer | Completed | USA | 3 |
NCT01969643 | Phase I | Ladiratuzumab vedotin Ladiratuzumab vedotin + Trastuzumab | A Safety Study of SGN-LIV1A in Breast Cancer Patients | Recruiting | USA | 0 |
NCT01982448 | Phase II | Paclitaxel Cisplatin | Cisplatin vs Paclitaxel for Triple Neg | Active, not recruiting | USA | 0 |
NCT01990209 | Phase II | Orteronel | Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) | Active, not recruiting | USA | 0 |
NCT01997333 | Phase II | Glembatumumab vedotin Capecitabine | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer | Completed | USA | CAN | 7 |
NCT01999738 | Phase I | EC1456 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02000882 | Phase II | Buparlisib + Capecitabine | Capecitabine + BKM120 TNBC BC Brain Met | Completed | USA | 0 |
NCT02003092 | Phase I | RX-5902 | RX-5902 Treatment of Subjects With Solid Tumors | Terminated | USA | 0 |
NCT02014337 | Phase I | Eribulin + Mifepristone | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Completed | USA | 0 |
NCT02032823 | Phase III | Olaparib | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA) | Active, not recruiting | USA | CAN | 22 |
NCT02071862 | Phase I | Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | Completed | USA | 0 |
NCT02078752 | Phase I | PF-06647263 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02101385 | Phase II | Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer | Active, not recruiting | USA | 0 | |
NCT02120469 | Phase I | Eribulin + Everolimus | Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT02138812 | Phase I | BAY1161909 + Paclitaxel | Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel | Terminated | USA | 0 |
NCT02157792 | Phase I | Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine | M6620 First in Human Study | Completed | USA | 1 |
NCT02158507 | Phase I | Lapatinib + Veliparib | Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02162719 | Phase II | Ipatasertib + Paclitaxel Paclitaxel | A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer | Completed | USA | 7 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02187991 | Phase II | Paclitaxel Alisertib + Paclitaxel | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | Active, not recruiting | USA | 0 |
NCT02203513 | Phase II | Prexasertib | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02208375 | Phase Ib/II | Capivasertib + Olaparib Olaparib + Vistusertib | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | Active, not recruiting | USA | 0 |
NCT02222922 | Phase I | Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin | A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | Completed | USA | 1 |
NCT02264678 | Phase Ib/II | AZD6738 AZD6738 + Carboplatin AZD6738 + Durvalumab AZD6738 + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | 3 |
NCT02276443 | Phase 0 | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | Recruiting | USA | 0 | |
NCT02281409 | Phase Ib/II | Mogamulizumab | Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02299635 | Phase II | PF-03084014 | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations | Terminated | USA | 5 |
NCT02307240 | Phase I | CUDC-907 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | Completed | USA | 0 |
NCT02322814 | Phase II | Cobimetinib + Paclitaxel Paclitaxel Atezolizumab + Cobimetinib + Paclitaxel Atezolizumab + Cobimetinib + Nab-paclitaxel | A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread | Active, not recruiting | USA | 12 |
NCT02358200 | Phase I | Carboplatin + Paclitaxel + Talazoparib | Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer | Terminated | USA | 0 |
NCT02365662 | Phase I | ABBV-221 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor | Terminated | USA | 1 |
NCT02366949 | Phase I | BAY1217389 + Paclitaxel Paclitaxel | Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel | Completed | USA | 1 |
NCT02368691 | Phase II | Enobosarm | Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) | Terminated | USA | 0 |
NCT02370238 | Phase II | Reparixin | A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer | Completed | USA | 6 |
NCT02375958 | Phase I | PCA062 | PCA062 in pCAD-positive Tumors. | Completed | USA | 5 |
NCT02393794 | Phase Ib/II | Cisplatin + Nivolumab + Romidepsin Cisplatin + Romidepsin | Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | Suspended | USA | 0 |
NCT02401347 | Phase II | Talazoparib | Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors | Recruiting | USA | 0 |
NCT02411656 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | Recruiting | USA | 0 |
NCT02419417 | Phase Ib/II | BMS986158 Paclitaxel | Study of BMS-986158 in Subjects With Select Advanced Solid Tumors | Recruiting | USA | CAN | 4 |
NCT02425891 | Phase III | Atezolizumab + Nab-paclitaxel Nab-paclitaxel | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | Active, not recruiting | USA | CAN | 39 |
NCT02427581 | Phase I | Poly ICLC | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | Recruiting | USA | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02435680 | Phase II | MCS110 Carboplatin + Gemcitabine | Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) | Completed | USA | 11 |
NCT02447003 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) | Completed | 0 | |
NCT02452424 | Phase Ib/II | Pembrolizumab + Pexidartinib | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | Terminated | USA | 0 |
NCT02456857 | Phase II | Bevacizumab Everolimus Pegylated liposomal-doxorubicin | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | Recruiting | USA | 0 |
NCT02457910 | Phase Ib/II | Enzalutamide Enzalutamide + Taselisib | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT02471846 | Phase I | GDC-0919 Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 3 |
NCT02474173 | Phase I | Paclitaxel Onalespib | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02489448 | Phase Ib/II | Durvalumab + Nab-paclitaxel Cyclophosphamide + Doxorubicin | Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02498613 | Phase II | Cediranib + Olaparib | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT02513472 | Phase Ib/II | Eribulin + Pembrolizumab | Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1) | Active, not recruiting | USA | 0 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | CAN | 2 |
NCT02530489 | Phase II | Atezolizumab + Nab-paclitaxel | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT02531932 | Phase II | Carboplatin Everolimus | Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer | Recruiting | USA | 0 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | 1 |
NCT02543645 | Phase Ib/II | Atezolizumab + Varlilumab | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT02554812 | Phase Ib/II | Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | Recruiting | USA | CAN | 6 |
NCT02555657 | Phase III | Pembrolizumab Eribulin Gemcitabine Vinorelbine Capecitabine | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | Completed | 0 | |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02574455 | Phase III | Sacituzumab govitecan-hziy Capecitabine + Eribulin + Gemcitabine + Vinorelbine | ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT) | Completed | USA | CAN | 5 |
NCT02575781 | Phase I | SAR428926 | A Study of SAR428926 in Patients With Advanced Solid Tumors | Completed | 3 | |
NCT02580448 | Phase Ib/II | VT-464 | A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer | Completed | USA | 0 |
NCT02593175 | Phase II | Carboplatin + Paclitaxel + Panitumumab | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | Recruiting | USA | 0 |
NCT02624700 | Phase II | Pemetrexed Disodium + Sorafenib | Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer | Terminated | USA | 0 |
NCT02627430 | Phase I | Onalespib + Talazoparib | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | Withdrawn | 0 | |
NCT02628535 | Phase I | MGD009 | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | 1 |
NCT02631733 | Phase I | Irinotecan + Veliparib | Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Suspended | USA | 0 |
NCT02632448 | Phase Ib/II | Gemcitabine + LY2880070 LY2880070 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | Recruiting | USA | CAN | 0 |
NCT02637375 | Phase I | Cyclophosphamide + Doxorubicin + Paclitaxel Ganetespib | A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer | Withdrawn | 0 | |
NCT02644369 | Phase II | Pembrolizumab | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) | Active, not recruiting | CAN | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02648477 | Phase II | Letrozole + Pembrolizumab Exemestane + Pembrolizumab Anastrozole + Pembrolizumab Doxorubicin + Pembrolizumab | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT02657889 | Phase Ib/II | Niraparib + Pembrolizumab | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO) | Active, not recruiting | USA | 0 |
NCT02658214 | Phase I | Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | Completed | 2 | |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | 5 |
NCT02672475 | Phase I | Galunisertib + Paclitaxel | Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02676986 | Phase II | Enzalutamide + Exemestane Exemestane Enzalutamide | Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB) | Active, not recruiting | USA | 4 |
NCT02689427 | Phase II | Enzalutamide + Paclitaxel | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | Recruiting | USA | 0 |
NCT02698176 | Phase I | Birabresib | A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) | Terminated | 0 | |
NCT02706392 | Phase I | Cyclophosphamide + Fludarabine + ROR1 CAR-T cells | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Recruiting | USA | 0 |
NCT02708680 | Phase Ib/II | Atezolizumab Atezolizumab + Entinostat | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | Unknown status | USA | 1 |
NCT02719691 | Phase I | Alisertib + Sapanisertib | Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02720185 | Phase II | Dasatinib | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR | Recruiting | USA | 0 |
NCT02730130 | Phase II | Pembrolizumab | Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients | Active, not recruiting | USA | 0 |
NCT02734290 | Phase Ib/II | Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab | Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | Active, not recruiting | USA | 0 |
NCT02750358 | Phase II | Enzalutamide | Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02752685 | Phase II | Nab-paclitaxel + Pembrolizumab | Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT02755272 | Phase II | Pembrolizumab Carboplatin + Gemcitabine | A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT02760797 | Phase I | Emactuzumab + Selicrelumab | A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | 2 |
NCT02761694 | Phase I | ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant | ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations | Active, not recruiting | USA | 0 |
NCT02762981 | Phase Ib/II | Nab-paclitaxel + Relacorilant | Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors | Completed | USA | 0 |
NCT02768701 | Phase II | Cyclophosphamide + Pembrolizumab | Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Recruiting | USA | CAN | 2 |
NCT02784795 | Phase I | Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Completed | USA | 3 |
NCT02788981 | Phase II | Mifepristone + Nab-paclitaxel Nab-paclitaxel | Abraxane With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer | Recruiting | USA | 0 |
NCT02807844 | Phase Ib/II | MCS110 + Spartalizumab | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | 10 |
NCT02819518 | Phase III | Paclitaxel Pembrolizumab Nab-paclitaxel Carboplatin + Gemcitabine | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | Active, not recruiting | 0 | |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | 5 |
NCT02826434 | Phase I | Durvalumab + Poly ICLC + PVX-410 | Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02829723 | Phase Ib/II | BLZ945 BLZ945 + Spartalizumab | Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | Recruiting | USA | 7 |
NCT02834247 | Phase I | Mivavotinib + Nivolumab | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | Terminated | USA | 3 |
NCT02834403 | Phase Ib/II | Pegfilgrastim Docetaxel + L-NMMA | L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients | Recruiting | USA | 0 |
NCT02876107 | Phase II | Cyclophosphamide + Doxorubicin Carboplatin + Paclitaxel + Panitumumab Carboplatin + Paclitaxel | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT02876302 | Phase II | Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | Recruiting | USA | 0 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02883062 | Phase II | Carboplatin + Paclitaxel Atezolizumab + Carboplatin + Paclitaxel | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02890069 | Phase I | LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Recruiting | USA | 6 |
NCT02898207 | Phase I | Olaparib + Onalespib | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02900664 | Phase I | Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) | Active, not recruiting | USA | CAN | 7 |
NCT02926690 | Phase I | OTS167 | Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT02929576 | Phase III | Paclitaxel Enzalutamide + Paclitaxel Enzalutamide | Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR) | Withdrawn | USA | 0 |
NCT02936102 | Phase I | FAZ053 FAZ053 + Spartalizumab | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | Active, not recruiting | USA | CAN | 7 |
NCT02938442 | Phase II | Montanide ISA 51 + P10s-PADRE | Vaccination of Triple Negative Breast Cancer Patients | Recruiting | USA | 0 |
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Active, not recruiting | USA | CAN | 7 |
NCT02950064 | Phase I | BTP-114 | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | Unknown status | USA | 0 |
NCT02952248 | Phase I | BI 754091 | A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours | Active, not recruiting | USA | CAN | 1 |
NCT02954874 | Phase III | Pembrolizumab | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | Recruiting | USA | CAN | 1 |
NCT02971761 | Phase II | Enobosarm + Pembrolizumab | Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02977468 | Phase I | Pembrolizumab | Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT) | Recruiting | USA | 0 |
NCT02978716 | Phase II | Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Trilaciclib | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) | Active, not recruiting | USA | 7 |
NCT02981303 | Phase II | Pembrolizumab + PGG beta-glucan | Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02984683 | Phase II | SAR566658 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | Completed | USA | 5 |
NCT02985658 | Phase I | Cisplatin Veliparib Vinorelbine | Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer | Available | USA | 0 |
NCT02996825 | Phase I | Gemcitabine + Mirvetuximab Soravtansine | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03004183 | Phase II | Pembrolizumab AdV-tk + Valacyclovir | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC | Active, not recruiting | USA | 0 |
NCT03012100 | Phase II | Cyclophosphamide + Sargramostim Cyclophosphamide + FR alpha peptide vaccine + Sargramostim | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03012230 | Phase I | Pembrolizumab + Ruxolitinib | Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03012477 | Phase II | Adavosertib + Cisplatin | CISPLATIN + AZD-1775 In Breast Cancer | Active, not recruiting | USA | 0 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Recruiting | USA | 1 |
NCT03036488 | Phase III | Cyclophosphamide + Epirubicin Cyclophosphamide + Doxorubicin Pembrolizumab Carboplatin + Paclitaxel | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | Active, not recruiting | USA | CAN | 19 |
NCT03044730 | Phase II | Capecitabine + Pembrolizumab | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03090165 | Phase Ib/II | Bicalutamide + Ribociclib | Ribociclib and Bicalutamide in AR+ TNBC | Active, not recruiting | USA | 0 |
NCT03095352 | Phase II | Carboplatin + Pembrolizumab + Trastuzumab Carboplatin Carboplatin + Trastuzumab Carboplatin + Pembrolizumab | Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease | Recruiting | USA | 0 |
NCT03098550 | Phase Ib/II | Daratumumab + Nivolumab | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread | Active, not recruiting | USA | CAN | 7 |
NCT03102320 | Phase I | Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) | Active, not recruiting | USA | CAN | 10 |
NCT03106077 | Phase II | Mirvetuximab Soravtansine | Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC) | Completed | USA | 0 |
NCT03106415 | Phase Ib/II | Binimetinib + Pembrolizumab | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03121352 | Phase II | Carboplatin + Nab-paclitaxel + Pembrolizumab | Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03125902 | Phase III | Paclitaxel Atezolizumab + Paclitaxel | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131) | Active, not recruiting | USA | CAN | 22 |
NCT03130439 | Phase II | Abemaciclib | Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT03150810 | Phase Ib/II | Pamiparib + Temozolomide | Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 3 |
NCT03167619 | Phase II | Durvalumab + Olaparib Olaparib | Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA) | Active, not recruiting | USA | 0 |
NCT03184558 | Phase II | Bemcentinib + Pembrolizumab | BGB324 in Combination With Pembrolizumab in Patients With TNBC | Completed | USA | 3 |
NCT03193853 | Phase II | Cisplatin + Nab-paclitaxel MLN1117 + Sapanisertib | TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03197935 | Phase III | Pegfilgrastim Doxorubicin Atezolizumab Filgrastim Nab-paclitaxel Cyclophosphamide | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031) | Active, not recruiting | USA | CAN | 11 |
NCT03199040 | Phase I | Durvalumab | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | Recruiting | USA | 0 |
NCT03206203 | Phase II | Atezolizumab + Carboplatin Carboplatin | Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03207867 | Phase II | PBF-509 + Spartalizumab | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | Recruiting | USA | 13 |
NCT03213041 | Phase II | Carboplatin + Pembrolizumab | Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT03221400 | Phase Ib/II | STA-8666 | PEN-866 in Patients With Advanced Solid Malignancies | Recruiting | USA | 0 |
NCT03225547 | Phase II | Mifepristone + Pembrolizumab | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | Recruiting | USA | 0 |
NCT03243331 | Phase I | Cofetuzumab pelidotin + Gedatolisib | An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer | Completed | USA | 0 |
NCT03256344 | Phase I | Atezolizumab + Talimogene laherparepvec | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | Active, not recruiting | USA | 5 |
NCT03281954 | Phase III | Atezolizumab | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | Recruiting | USA | CAN | 0 |
NCT03289962 | Phase I | RO7198457 Atezolizumab + RO7198457 | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Recruiting | USA | CAN | 6 |
NCT03292172 | Phase I | Atezolizumab + TEN-010 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | Terminated | USA | CAN | 3 |
NCT03310957 | Phase Ib/II | Ladiratuzumab vedotin + Pembrolizumab | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | Recruiting | USA | 3 |
NCT03316586 | Phase II | Cabozantinib + Nivolumab | A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03316794 | Phase I | SC-005 | A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) | Terminated | USA | 0 |
NCT03318562 | Phase II | Tomivosertib | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | Terminated | USA | 0 |
NCT03330405 | Phase II | Avelumab + Talazoparib | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | Active, not recruiting | USA | CAN | 7 |
NCT03330847 | Phase II | Adavosertib + Olaparib Olaparib AZD6738 + Olaparib | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. | Active, not recruiting | USA | CAN | 13 |
NCT03337724 | Phase II | Ipatasertib + Paclitaxel Paclitaxel | A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130) | Active, not recruiting | USA | CAN | 28 |
NCT03361800 | Phase I | Entinostat | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC | Active, not recruiting | USA | 0 |
NCT03362060 | Phase I | Pembrolizumab + PVX-410 | PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03363893 | Phase Ib/II | ICEC0942 Fulvestrant + ICEC0942 | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | Recruiting | USA | 1 |
NCT03366844 | Phase Ib/II | Pembrolizumab | Breast Cancer Study of Preoperative Pembrolizumab + Radiation | Active, not recruiting | USA | 0 |
NCT03371017 | Phase III | Atezolizumab + Capecitabine + Carboplatin + Gemcitabine Capecitabine + Carboplatin + Gemcitabine | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132) | Recruiting | USA | 28 |
NCT03387085 | Phase Ib/II | ETBX-051 Aldoxorubicin ETBX-061 Cisplatin Cyclophosphamide haNK cells GI-4000 Bevacizumab ALT-803 Fluorouracil ETBX-011 Oxaliplatin Capecitabine Leucovorin GI-6301 Nab-paclitaxel Avelumab GI-6207 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | Active, not recruiting | USA | 0 |
NCT03414684 | Phase II | Carboplatin + Nivolumab Carboplatin | Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03424005 | Phase Ib/II | Atezolizumab + Bevacizumab + Selicrelumab Atezolizumab + RO6874281 Atezolizumab + Bevacizumab Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Eribulin Capecitabine Atezolizumab Atezolizumab + Bevacizumab + Cobimetinib Atezolizumab + Capecitabine Atezolizumab + Ipatasertib Atezolizumab + Ladiratuzumab vedotin | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) | Recruiting | USA | 7 |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Active, not recruiting | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Recruiting | USA | 1 |
NCT03483012 | Phase II | Atezolizumab | Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis | Active, not recruiting | USA | 0 |
NCT03487666 | Phase II | Capecitabine + Nivolumab Capecitabine Nivolumab | OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease | Recruiting | USA | 0 |
NCT03498716 | Phase III | Atezolizumab + Cyclophosphamide + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel Atezolizumab + Cyclophosphamide + Doxorubicin + Paclitaxel | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030) | Recruiting | USA | 29 |
NCT03499899 | Phase II | Carboplatin + LAG525 Carboplatin + LAG525 + Spartalizumab LAG525 + Spartalizumab | A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | Active, not recruiting | USA | CAN | 15 |
NCT03504488 | Phase Ib/II | BA3021 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors | Recruiting | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Recruiting | USA | 0 |
NCT03519178 | Phase II | PF-06873600 | A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy | Recruiting | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03542175 | Phase I | Rucaparib | A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy | Recruiting | USA | 0 |
NCT03544125 | Phase I | Durvalumab + Olaparib | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer | Completed | USA | 0 |
NCT03546686 | Phase II | Ipilimumab + Nivolumab | Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer | Recruiting | USA | 0 |
NCT03554109 | Phase II | Aldoxorubicin + ALT-803 + Avelumab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | Withdrawn | USA | 0 |
NCT03556228 | Phase I | VMD-928 | Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma | Recruiting | USA | 0 |
NCT03562637 | Phase III | Adagloxad simolenin + OBI-821 | Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | Recruiting | USA | 6 |
NCT03564782 | Phase I | PVSRIPO | Examining Bioactivity of PVSRIPO in Invasive Breast Cancer | Recruiting | USA | 0 |
NCT03567720 | Phase II | Pembrolizumab + Tavokinogene telseplasmid Nab-paclitaxel + Pembrolizumab + Tavokinogene telseplasmid | Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC | Recruiting | USA | 1 |
NCT03579472 | Phase I | Eribulin + M7824 | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03599453 | Phase I | Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod | Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03606967 | Phase II | Durvalumab + Nab-paclitaxel + Poly ICLC + Tremelimumab + TSMA-based SLP vaccine Nab-paclitaxel Carboplatin + Gemcitabine Durvalumab + Nab-paclitaxel + Tremelimumab | Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03621982 | Phase I | Camidanlumab Tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03639948 | Phase II | Carboplatin + Docetaxel + Pegfilgrastim + Pembrolizumab | Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer (NeoPACT) | Recruiting | USA | 0 |
NCT03644589 | Phase II | Cisplatin + Pembrolizumab | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer | Withdrawn | USA | 0 |
NCT03654547 | Phase I | TT-00420 | Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03661632 | Phase Ib/II | BMS-986310 + Nivolumab | An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 3 |
NCT03665285 | Phase Ib/II | NC318 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT03667716 | Phase I | COM701 COM701 + Nivolumab | COM701 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03674567 | Phase Ib/II | FLX475 + Pembrolizumab FLX475 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | Recruiting | USA | 5 |
NCT03674827 | Phase I | PF-06936308 | A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC | Recruiting | USA | 0 |
NCT03681951 | Phase Ib/II | GSK3145095 GSK3145095 + Pembrolizumab | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Recruiting | USA | 0 |
NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
NCT03709446 | Phase Ib/II | Leflunomide | Leflunomide in Previously Treated Metastatic Triple Negative Cancers | Recruiting | USA | 0 |
NCT03719326 | Phase I | AB928 + IPI-549 + Pegylated liposomal-doxorubicin AB928 + Pegylated liposomal-doxorubicin | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | Active, not recruiting | USA | 1 |
NCT03733119 | Phase II | ONC201 | ONC201 With and Without Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer | Suspended | USA | 0 |
NCT03742102 | Phase Ib/II | Durvalumab + Oleclumab + Paclitaxel Durvalumab + Trastuzumab deruxtecan Durvalumab + Paclitaxel Capivasertib + Durvalumab + Paclitaxel | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA) | Recruiting | USA | CAN | 4 |
NCT03742349 | Phase I | Canakinumab + LAG525 + Spartalizumab LAG525 + MCS110 + Spartalizumab Capmatinib + LAG525 + Spartalizumab LAG525 + PBF-509 + Spartalizumab | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | Recruiting | USA | 8 |
NCT03752398 | Phase I | XmAb23104 | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Recruiting | USA | 0 |
NCT03761914 | Phase Ib/II | Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Recruiting | USA | 0 |
NCT03775850 | Phase Ib/II | EDP1503 EDP1503 + Pembrolizumab | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | Recruiting | USA | CAN | 0 |
NCT03797326 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | Recruiting | USA | CAN | 8 |
NCT03800836 | Phase I | Atezolizumab + Ipatasertib + Paclitaxel Atezolizumab + Ipatasertib + Nab-paclitaxel | A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | Active, not recruiting | USA | 4 |
NCT03801369 | Phase II | Durvalumab + Olaparib | Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03812393 | Phase II | Carboplatin + Neratinib + Paclitaxel Neratinib | Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (FACT-2) | Recruiting | USA | 0 |
NCT03821935 | Phase I | ABBV-151 ABBV-151 + ABBV-181 | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 9 |
NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Recruiting | USA | 3 |
NCT03838367 | Phase Ib/II | Carboplatin + Leronlimab | Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC | Recruiting | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Recruiting | USA | 0 |
NCT03853707 | Phase Ib/II | Carboplatin + Ipatasertib + Paclitaxel Carboplatin + Ipatasertib Atezolizumab + Capecitabine + Ipatasertib | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03861403 | Phase Ib/II | Avelumab + Cyclophosphamide + TRX518 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03872388 | Phase II | Atorvastatin + Capecitabine Capecitabine | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | Recruiting | USA | 0 |
NCT03872505 | Phase II | Carboplatin + Durvalumab + Paclitaxel | Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer (PANDoRA) | Not yet recruiting | USA | 0 |
NCT03875313 | Phase Ib/II | Talazoparib + Telaglenastat | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03891953 | Phase I | DKY709 DKY709 + Spartalizumab | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | Recruiting | USA | 4 |
NCT03893955 | Phase I | ABBV-368 + ABBV-927 + Nab-paclitaxel ABBV-368 + ABBV-927 ABBV-181 + ABBV-368 + ABBV-927 ABBV-181 + ABBV-927 + Carboplatin ABBV-927 + Carboplatin ABBV-368 + ABBV-927 + Carboplatin | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 5 |
NCT03901469 | Phase II | Talazoparib + ZEN-3694 | A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC) | Recruiting | USA | 2 |
NCT03911453 | Phase I | Rucaparib | Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | Recruiting | USA | 0 |
NCT03911973 | Phase Ib/II | Gedatolisib + Talazoparib | Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers | Recruiting | USA | 0 |
NCT03917381 | Phase Ib/II | GEN1046 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Recruiting | USA | 4 |
NCT03941730 | Phase II | Estradiol | Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT03945721 | Phase I | Niraparib | A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients | Recruiting | USA | 0 |
NCT03950570 | Phase I | ORIN1001 + Paclitaxel ORIN1001 | ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT03952325 | Phase II | Pembrolizumab + Tesetaxel Nivolumab + Tesetaxel Tesetaxel Atezolizumab + Tesetaxel | Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC (CONTESSA TRIO) | Recruiting | USA | 2 |
NCT03961698 | Phase II | Atezolizumab + Bevacizumab + IPI-549 Atezolizumab + IPI-549 + Nab-paclitaxel | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) (MARIO-3) | Recruiting | USA | 0 |
NCT03971409 | Phase II | Avelumab + PF-04518600 Avelumab + Utomilumab Avelumab + Binimetinib | Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer (InCITe) | Recruiting | USA | 0 |
NCT03977467 | Phase II | Atezolizumab + Carboplatin Atezolizumab + Cisplatin Atezolizumab Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin | Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | Recruiting | USA | 0 |
NCT03979508 | Phase II | Abemaciclib | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03990896 | Phase II | Talazoparib | Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | Recruiting | USA | 0 |
NCT03992131 | Phase Ib/II | Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan-hziy | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) | Recruiting | USA | 0 |
NCT03997123 | Phase III | Paclitaxel Capivasertib + Paclitaxel | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CapItello290) | Recruiting | USA | CAN | 27 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04024436 | Phase II | Fulvestrant + Futibatinib Futibatinib | A Study of TAS-120 in Patients With Metastatic Breast Cancer | Recruiting | USA | 5 |
NCT04024800 | Phase II | AE37 + Pembrolizumab | Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14) | Recruiting | USA | 0 |
NCT04032080 | Phase II | Prexasertib LY3023414 | Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib (ExIST) | Recruiting | USA | 0 |
NCT04039230 | Phase Ib/II | Sacituzumab govitecan-hziy + Talazoparib | Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. | Recruiting | USA | 0 |
NCT04041128 | Phase I | Olaparib | PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer | Recruiting | USA | 0 |
NCT04052555 | Phase I | Berzosertib | Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer | Recruiting | USA | 0 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Recruiting | USA | 1 |
NCT04081389 | Phase I | Celecoxib + Cyclophosphamide + Doxorubicin + Interferon alpha-2b + Paclitaxel + Rintatolimod | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT04095689 | Phase II | Cyclophosphamide + Docetaxel + Doxorubicin + IL-12 gene + L-NMMA + Pembrolizumab | TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer | Not yet recruiting | USA | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04111510 | Phase II | LN-145 | Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT04115306 | Phase I | PMD-026 | Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT04152499 | Phase Ib/II | SKB264 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Recruiting | USA | 1 |
NCT04176848 | Phase II | CFI-400945 + Durvalumab | CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer | Recruiting | CAN | 0 |
NCT04177108 | Phase III | Ipatasertib + Paclitaxel Atezolizumab + Paclitaxel Atezolizumab + Ipatasertib + Paclitaxel Paclitaxel | A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. | Active, not recruiting | USA | CAN | 36 |
NCT04185311 | Phase I | Ipilimumab + Nivolumab + Talimogene laherparepvec | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | Recruiting | USA | 0 |
NCT04191135 | Phase II | Carboplatin + Gemcitabine + Pembrolizumab Carboplatin + Gemcitabine + Olaparib + Pembrolizumab | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | Recruiting | USA | CAN | 13 |
NCT04216472 | Phase II | Alpelisib + Nab-paclitaxel | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | Recruiting | USA | 0 |
NCT04225117 | Phase II | Enfortumab vedotin-ejfv | A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Recruiting | USA | 1 |
NCT04230109 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan In TNBC (NeoSTAR) | Recruiting | USA | 0 |
NCT04243616 | Phase II | Carboplatin + Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel | Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer | Recruiting | USA | 0 |
NCT04249167 | Phase I | Atezolizumab + Nab-paclitaxel | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT04251533 | Phase III | Alpelisib + Nab-paclitaxel Nab-paclitaxel | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation (EPIK-B3) | Recruiting | USA | 22 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04265872 | Phase I | Bortezomib + Cisplatin + Pembrolizumab | Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC | Recruiting | USA | 0 |
NCT04300556 | Phase Ib/II | MORAb-202 | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FR alpha)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Recruiting | USA | 0 |
NCT04301011 | Phase Ib/II | TBio-6517 Pembrolizumab + TBio-6517 | Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors (RAPTOR) | Recruiting | USA | 0 |
NCT04315233 | Phase I | Belinostat + Ribociclib | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE) | Recruiting | USA | 0 |
NCT04331067 | Phase Ib/II | Cabiralizumab + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Paclitaxel | Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer | Recruiting | USA | 0 |
NCT04332653 | Phase Ib/II | NT-I7 + Pembrolizumab | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60) | Recruiting | USA | 0 |
NCT04344795 | Phase I | TPST-1495 Pembrolizumab + TPST-1495 | Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT04345913 | Phase Ib/II | Eribulin Copanlisib + Eribulin | Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT04348747 | Phase II | Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Rintatolimod | Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | Not yet recruiting | USA | 0 |
NCT04373031 | Phase II | Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Doxorubicin + IRX-2 + Paclitaxel + Pembrolizumab | Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT04423029 | Phase Ib/II | DF6002 + Pembrolizumab DF6002 | Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications | Recruiting | USA | 0 |
NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Recruiting | USA | 3 |
NCT04427293 | Phase I | Lenvatinib + Pembrolizumab | Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) | Recruiting | USA | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04432857 | Phase I | E7046 + Pembrolizumab | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04434040 | Phase II | Atezolizumab + Ipatasertib | Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC | Suspended | USA | 0 |
NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Recruiting | USA | 0 |
NCT04441099 | Phase Ib/II | NBE-002 | NBE-002 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04443348 | Phase II | Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab | Pre-op Pembro + Radiation Therapy in Breast Cancer | Recruiting | USA | 0 |
NCT04445844 | Phase II | Pelareorep + Retifanlimab | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | Recruiting | USA | 0 |
NCT04454528 | Phase Ib/II | Pembrolizumab | BreastVax: Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer | Recruiting | USA | 0 |
NCT04461600 | Phase II | BMS-906024 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY) | Recruiting | USA | 1 |
NCT04468061 | Phase II | Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Recruiting | USA | 0 |
NCT04489940 | Phase II | M7824 | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | Recruiting | USA | 5 |
NCT04504669 | Phase I | AZD8701 + Durvalumab AZD8701 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Recruiting | USA | CAN | 2 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Recruiting | USA | CAN | 5 |
NCT04553133 | Phase II | PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 | PF-07104091 as a Single Agent and in Combination Therapy | Recruiting | USA | 0 |
NCT04561362 | Phase Ib/II | BT8009 BT8009 + Nivolumab | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies | Recruiting | USA | 1 |
NCT04574583 | Phase Ib/II | FPV-CV301 + M7824 + MVA-BN-CV301 + SX-682 | Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) | Recruiting | USA | 0 |
NCT04580485 | Phase I | INCB106385 + Retifanlimab INCB106385 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04584112 | Phase I | Atezolizumab + Cyclophosphamide + Doxorubicin + MTIG7192A + Pegfilgrastim Atezolizumab + Cyclophosphamide + Doxorubicin + MTIG7192A + Sargramostim Atezolizumab + MTIG7192A + Nab-paclitaxel Atezolizumab + Cyclophosphamide + Doxorubicin + Filgrastim + MTIG7192A | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | Recruiting | USA | 8 |
NCT04592653 | Phase II | ALKS 4230 + Pembrolizumab | A Study of ALKS 4230 on the Tumor Microenvironment (ARTISTRY-3) | Recruiting | USA | 0 |
NCT04596150 | Phase II | CX-2009 CX-072 + CX-2009 | Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer | Recruiting | USA | 0 |
NCT04622774 | Phase I | IMGC936 | First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04639245 | Phase Ib/II | MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | Not yet recruiting | USA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b First-In-Human (FIH) Study of PY159 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04683679 | Phase II | Olaparib + Pembrolizumab Pembrolizumab | A Study of Radiation Therapy With Pembrolizumab and Olaparib in Women Who Have Triple-Negative Breast Cancer | Not yet recruiting | USA | 0 |
NCT04726332 | Phase I | Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT04762901 | Phase I | Cyclophosphamide + Doxorubicin + Niraparib + Pegfilgrastim Cyclophosphamide + Doxorubicin + Niraparib Niraparib + Paclitaxel Carboplatin + Niraparib + Paclitaxel | LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | Not yet recruiting | USA | 0 |